Jiangsu Key Laboratory of Pediatric Respiratory Disease, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; Jiangsu Provincial Traditional Chinese Medicine High Efficient Drug Delivery System Engineering Technology Research Center, Nanjing 210023, PR China.
Jiangsu Key Laboratory of Pediatric Respiratory Disease, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; Jiangsu Provincial Traditional Chinese Medicine High Efficient Drug Delivery System Engineering Technology Research Center, Nanjing 210023, PR China.
Chem Biol Interact. 2016 Oct 25;258:187-96. doi: 10.1016/j.cbi.2016.09.005. Epub 2016 Sep 6.
Ginsenoside Rb1, an active ingredient in Panax ginseng, was widely used for its various biological activities. To clarify the role of the gut microbiota in pharmacokinetics and metabolism of Rb1, a comprehensive and comparative study of colonic deglycosylation metabolism and systemic exposure of ginsenoside Rb1 in normal rats, antimicrobials (ATMs) treated rats, and restraint stressed rats was conducted. ATMs treated rats received oral administration of non-absorbable antimicrobial mixtures for 7 consecutive days. Restraint stressed rats were subjected to repeated restraint stress for a period of 2 h once daily for 7 days. Plasma concentration dynamics, urine and fecal excretion of Rb1 and its deglycosylation metabolites (Rd, F2, and C-K) were studied. Moreover, the in vitro metabolism of Rb1 in fecal suspension and the fecal β-d-glucosidase activity were profiled. Systemic exposure of the deglycosylation metabolites of ginsenoside Rb1 (F2, C-K) were significantly higher in restraint stressed rats, but ATMs treated rats exhibited a decreased plasma levels of F2 and C-K, compared with normal rats. Further studies illustrated that altered systemic Rb1 and its deglycosylation metabolites exposure in restraint-stressed rats and ATMs treated rats may be partially attributed to alternations in cumulative fecal excretion. The distinguishing fecal β-d-glucosidase, in vitro elimination of Rb1, and formation of these deglycosylation metabolites afforded further evidence for the in vivo data. In conclusion, the dys-regulated fecal β-d-glucosidase activity and deglycosylation metabolism may contribute to the altered pharmacokinetic of ginsenoside Rb1 and its hydrolysis metabolites after ATMs treatment or restraint stress exposure. Our results may offer valuable insights into the pharmacological changes of bioactive ginsenosides in dys-regulated gut microbiota statue.
人参皂苷 Rb1 是人参中的一种活性成分,因其具有多种生物活性而被广泛应用。为了阐明肠道微生物群在人参皂苷 Rb1 的药代动力学和代谢中的作用,我们对正常大鼠、使用抗生素(ATMs)处理的大鼠和束缚应激大鼠进行了结肠去糖基化代谢和系统暴露人参皂苷 Rb1 的综合和比较研究。使用抗生素(ATMs)处理的大鼠连续 7 天口服非吸收性抗生素混合物。束缚应激大鼠每天接受 1 次、每次 2 小时的重复束缚应激,持续 7 天。研究了 Rb1 及其去糖基化代谢物(Rd、F2 和 C-K)在血浆中的浓度动力学、尿液和粪便中的排泄情况。此外,还对粪便悬浮液中 Rb1 的体外代谢以及粪便 β-d-葡萄糖苷酶活性进行了分析。与正常大鼠相比,束缚应激大鼠的人参皂苷 Rb1 去糖基化代谢物(F2、C-K)的系统暴露显著增加,而使用抗生素(ATMs)处理的大鼠的 F2 和 C-K 血浆水平降低。进一步的研究表明,束缚应激大鼠和使用抗生素(ATMs)处理的大鼠中 Rb1 及其去糖基化代谢物的系统暴露改变可能部分归因于粪便累积排泄的改变。有区别的粪便 β-d-葡萄糖苷酶、体外消除 Rb1 以及这些去糖基化代谢物的形成,为体内数据提供了进一步的证据。总之,肠道微生物失调引起的粪便 β-d-葡萄糖苷酶活性和去糖基化代谢的改变可能导致使用抗生素(ATMs)处理或束缚应激暴露后人参皂苷 Rb1 及其水解代谢物的药代动力学改变。我们的研究结果可为失调的肠道微生物群状态下生物活性人参皂苷的药理变化提供有价值的见解。